Registered title, quoted from ClinicalTrials.gov
The Comparison Between M-E-BCS and C-O-BCS.
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07539545, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
preoperative pathological examination confirmed it as invasive breast cancer or ductal carcinoma in situ;
Inclusion criterion 2
the tumor is more than 2 cm away from the nipple (the distance is based on physical examination, with MRI and ultrasound as supplementary methods);
Inclusion criterion 6
breast cancer genetic gene mutations (such as BRCA1/2 gene mutations);
Exclusion criterion 6
pregnant and lactating women;
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07539545, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- female patients aged 18-70 years (inclusive);
- preoperative pathological examination confirmed it as invasive breast cancer or ductal carcinoma in situ;
- both clinical and imaging examinations clearly indicated that the lesion was a single lesion confined within the gland, without invasion of the skin, subcutaneous tissue, pectoralis major muscle, or the nipple-areola complex;
- tumors in the inner and outer quadrants (three classification method, as shown in Figure 2);
- preoperative tumor size ≤3 cm (pre-neoadjuvant chemotherapy if applicable);
- the tumor is more than 2 cm away from the nipple (the distance is based on physical examination, with MRI and ultrasound as supplementary methods);
- the patient has a clear intention to preserve the breast and can receive standard radiotherapy after the operation;
- voluntary provision of informed consent. .
Exclusion Criteria:
- clinically or radiologically evaluated as multifocal or multicentric breast cancer, with diffuse suspicious calcification, long spiculated masses, extensive local resection unable to obtain sufficient negative margins or ideal shape;
- persistent positive tumor margins, and resection cannot ensure negative margins after resection;
- inflammatory breast cancer;
- pregnant and lactating women;
- previous history of breast cancer surgery (including patients with recurrence after ipsilateral breast-conserving surgery);
- breast cancer genetic gene mutations (such as BRCA1/2 gene mutations);
- preoperative severe underlying diseases that cannot tolerate general anesthesia and surgical procedures.
- other situations that the researchers consider unsuitable for participation
Quoted from ClinicalTrials.gov, NCT07539545, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07539545, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.